X
AKBA icon

Xponance’s Akebia Therapeutics AKBA Stock Holding History

Xponance’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$28.1K Buy
24,606
+1,824
+8% +$2.17K ﹤0.01% 1816
2026
Q1 		$31.7K Buy
22,782
+2,837
+14% +$3.9K ﹤0.01% 1655
2025
Q4 		$32.1K Buy
19,945
+399
+2% +$835 ﹤0.01% 1550
2025
Q3 		$53.4K Buy
19,546
+217
+1% +$722 ﹤0.01% 1485
2025
Q2 		$70.4K Buy
19,329
+3,529
+22% +$9.7K ﹤0.01% 1440
2025
Q1 		$30.3K Buy
15,800
+1,511
+11% +$3.08K ﹤0.01% 1414
2024
Q4 		$27.1K Buy
14,289
+588
+4% +$1.02K ﹤0.01% 1430
2024
Q3 		$18.1K Hold
13,701
– – ﹤0.01% 1382
2024
Q2 		$14K Buy
+13,701
New +$16.9K ﹤0.01% 1314

Other funds holding AKBA

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $27.8B AUM 46.46% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Xponance's AKBA Position: Q2 2026 in Review

Xponance increased its Akebia Therapeutics (AKBA) stake by 8% in Q2 2026, buying an estimated $2.17K and bringing the position to 24,606 shares worth $28.1K. The position accounts for ﹤0.01% of the portfolio, ranked #1816.

Xponance first reported a position in AKBA in Q2 2024 and has held it in 9 quarters since. The position peaked at $70.4K in Q2 2025. 170 funds tracked by Wall St. Rank hold AKBA as of Q2 2026.

  • Xponance held 24,606 shares of Akebia Therapeutics worth $28.1K as of Q2 2026.
  • Xponance bought 1,824 Akebia Therapeutics shares in Q2 2026, an estimated $2.17K.
  • Akebia Therapeutics made up ﹤0.01% of Xponance's portfolio in Q2 2026, its #1816 holding.
  • Xponance first reported a position in Akebia Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Xponance's Akebia Therapeutics position peaked at $70.4K in Q2 2025.
  • 170 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q2 2026.

Based on Xponance's 13F filing for Q2 2026, filed 10 Aug 2026.